<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946385</url>
  </required_header>
  <id_info>
    <org_study_id>205613</org_study_id>
    <secondary_id>V102_15E1</secondary_id>
    <secondary_id>2016-002230-69</secondary_id>
    <nct_id>NCT02946385</nct_id>
  </id_info>
  <brief_title>Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents</brief_title>
  <official_title>A Phase 2b Open-Label Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 Years After the Last Meningococcal Vaccination in Study V102_15 (NCT02212457) and the Response to a Booster Dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the persistence of 2 or 3 doses of the GSK MenABCWY
      vaccine, or 2 doses of GSK rMenB+OMV vaccine (Bexsero) administered to healthy adolescents at
      approximately 24 months after the last meningococcal vaccination in the parent study
      V102_15(NCT02212457), compared with baseline antibody levels in vaccine naïve subjects at
      similar age at enrolment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naive subjects will be randomized 1:1 to receive MenABCWY or rMenB+OMV at Day 1. No
      randomization to treatment arm for follow-on subjects is required as vaccine groups remain
      the same as in the parent study V102_15 (NCT02212457).

      Response to a booster dose of MenABCWY vaccine will also be assessed in follow-on subjects
      who received 2 or 3 doses of MenABCWY (at 0.2-, 0,.6- or 0,.2,.6-month schedules) in the
      parent study, and will be compared with responses to a single dose of MenABCWY in naive
      subjects (subjects who are meningococcal vaccine-naive and of similar age to subjects
      enrolled from the parent study).

      Response to a booster dose of GSK Meningococcal B Recombinant vaccine (rMenB+OMV) will be
      assessed in subjects who received 2 doses of rMenB+OMV (at 0, 2-month schedule) in the parent
      study, and will be compared with responses to a single dose of rMenB+OMV in naive subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">February 13, 2018</completion_date>
  <primary_completion_date type="Actual">February 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last Meningococcal Vaccination in Follow-on Subjects in V102_15 and at Day 1 in Naive Subjects</measure>
    <time_frame>At 24 months after the last meningococcal vaccination for all follow-on subjects and at Day 1 in the extension study for naive subjects</time_frame>
    <description>The immunogenicity of MenABCWY or rMenB+OMV vaccines, is measured as the percentage of subjects with High-Throughput Human Serum Bactericidal Assay (HT-hSBA) titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last Meningococcal Vaccination in Follow-on Subjects in V102_15 and at Day 1 in Naive Subjects</measure>
    <time_frame>At 24 months after the last meningococcal vaccination for all follow-on subjects and at Day 1 in the extension study for naive subjects</time_frame>
    <description>The immunogenicity of MenABCWY or rMenB+OMV vaccines, is measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers ≥ LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</measure>
    <time_frame>Day 31: One month after a booster dose of MenABCWY given at 24 months after last MenABCWY vaccination in groups: ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 and after first dose of MenABCWY in Naive_ABCWY Group</time_frame>
    <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with HT-hSBA titers greater than or equal to (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</measure>
    <time_frame>Day 31: One month after a booster dose of MenABCWY given at 24 months after last MenABCWY vaccination in groups: ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 and after first dose of MenABCWY in Naive_ABCWY Group</time_frame>
    <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</measure>
    <time_frame>Day 31: One month after a booster dose of MenABCWY given at 24 months after last MenABCWY vaccination in groups: ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 and after first dose of MenABCWY in Naive_ABCWY Group</time_frame>
    <description>The immunogenicity of MenABCWY vaccine, was measured as the HT-hSBA Geometric Mean Titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y . The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and N. Meningitidis Serogroups A, C, W and Y at 24 Months At Days 1, 6, 31 in V102_15 Follow-on Subjects and at Day 1, 66, 91 in Naive Subjects, in MenABCWY Groups</measure>
    <time_frame>At Day 1, Day 6 and 31(after booster dose of MenABCWY given at 24 months after last MenABCWY vaccination) in ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 groups and at Day 1, Day 66 and 91(i.e. day 6 and 1 month after dose 2 of MenABCWY) in Naive_ABCWY Group</time_frame>
    <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y At Days 6, 31 in Follow-on Subjects in V102_15 and at Day 66, 91 in Naive Subjects, in MenABCWY Groups</measure>
    <time_frame>At Day 6 and 31(after booster dose of MenABCWY given at 24 months after last MenABCWY vaccination) in ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 groups and at Day 66 and 91(i.e. day 6 and 1 month after dose 2 of MenABCWY) in Naive_ABCWY Group</time_frame>
    <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in MenABCWY Groups</measure>
    <time_frame>At Day 1, Day 6 and 31(after booster dose of MenABCWY given at 24 months after last MenABCWY vaccination) in ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 groups and at Day 1, Day 66 and 91(i.e. day 6 and 1 month after dose 2 of MenABCWY) in Naive_ABCWY Group</time_frame>
    <description>The immunogenicity of MenABCWY vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y . The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HT-hSBA Titers ≥ LLOQ Against 4 Serogroup B Test Strains at Day 31 After rMenB+OMV Vaccination in V102_15E1</measure>
    <time_frame>Day 31: One month after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMVl vaccination in B_0_2 Group and after first dose of rMenB+OMV in Naive_B Group</time_frame>
    <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains at Day 31 After rMenB+OMV Vaccination in V102_15E1</measure>
    <time_frame>Day 31: One month after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination in B_0_2 Group and after first dose of rMenB+OMV in Naive_B Group</time_frame>
    <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs Against Each of Four Serogroup B Test Strains, at Day 31 After rMenB+OMV Vaccination in V102_15E1</measure>
    <time_frame>Day 31: One month after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination in B_0_2 Group and after first dose of rMenB+OMV in Naive_B Group</time_frame>
    <description>The immunogenicity of rMenB+OMV vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains at 24 Months At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in rMenB+OMV Groups</measure>
    <time_frame>At Day 1, at Day 6 and 31(after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination) in B_0_2 Group, and at Day 1, at Day 66 and 91(i.e. day 6 and 1 month after second dose of rMenB+OMV) in Naive_B Group</time_frame>
    <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains At Days 6, 31 in Follow-on Subjects in V102_15 and at Day 66, 91 in Naive Subjects, in rMenB+OMV Groups</measure>
    <time_frame>At Day 6 and 31(after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination) in B_0_2 Group, and at Day 66 and 91(i.e. day 6 and 1 month after second dose of rMenB+OMV) in Naive_B Group</time_frame>
    <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs Against Each of Four Serogroup B Test Strains At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in rMenB+OMV Groups</measure>
    <time_frame>At Day 1, at Day 6 and 31(after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination) in B_0_2 Group, and at Day 1, at Day 66 and 91(i.e. day 6 and 1 month after second dose of rMenB+OMV) in Naive_B Group</time_frame>
    <description>The immunogenicity of rMenB+OMV vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination</measure>
    <time_frame>within 30 minutes after vaccination at Day 1 (for all subjects) and also Day 61 (for naive subjects only)</time_frame>
    <description>Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited AEs Within 30 Minutes After Vaccination</measure>
    <time_frame>Within 30 minutes after vaccination at Day 1 (for all subjects) and also Day 61 (for naive subjects only)</time_frame>
    <description>An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a subject and/or parent/legal guardian who has signed the informed consent. Number of subjects reporting any unsolicited AE within 30 minutes after each vaccination. Note: unsolicited AEs within 30 minutes were not collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.</measure>
    <time_frame>At Day 1 (6 hours) to Day 7 after vaccination at Day 1 (for all subjects) and Day 61 to Day 67 (for naive subjects only)</time_frame>
    <description>Assessed solicited symptoms were pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs, 30 Days After Any Vaccination</measure>
    <time_frame>From Day 1 to Day 31 for all subjects and Day 61 to Day 91 for naive subjects</time_frame>
    <description>An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a subject and/or parent/legal guardian who has signed the informed consent. Number of subjects reporting any unsolicited AE within 30 minutes after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal</measure>
    <time_frame>During the entire study period (up to Day 181 for follow-on subjects and up to Day 241 for naive subjects)</time_frame>
    <description>Serious adverse events (SAEs), medically attended adverse events and AEs leading to withdrawal are reported. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in one or more of the following: -Death, -Is life-threatening,-Required or prolonged hospitalization, -Persistent or significant disability/incapacity, -Congenital anomaly/or birth defect, -An important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">604</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>ABCWY_ 0_2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABCWY_0_2_6 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_0_2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABCWY_ 0_6 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABCWY Naive Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rMenB+OMV Naive Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal ABCWY Vaccine</intervention_name>
    <description>Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.</description>
    <arm_group_label>ABCWY Naive Group</arm_group_label>
    <arm_group_label>ABCWY_ 0_2 Group</arm_group_label>
    <arm_group_label>ABCWY_ 0_6 Group</arm_group_label>
    <arm_group_label>ABCWY_0_2_6 Group</arm_group_label>
    <other_name>MenABCWY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B Recombinant vaccine</intervention_name>
    <description>Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.</description>
    <arm_group_label>B_0_2 Group</arm_group_label>
    <arm_group_label>rMenB+OMV Naive Group</arm_group_label>
    <other_name>rMenB+OMV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Follow-on Participants

          -  Subjects from Finland and Poland previously enrolled in study V102_15 (NCT02212457)
             who have received all planned meningococcal vaccinations in the study

          -  Who have not received any additional meningococcal vaccination since the last
             meningococcal vaccination administered in the parent trial.

          -  Who have given written informed consent or assent after the nature of the study has
             been explained according to local regulatory requirements, prior to study entry. If
             the subject is under age 18 at the time of enrollment, the parent(s)/ legal
             guardian(s) of the subject should have given their written consent.

          -  Individuals of who the investigator believes can and will comply with the requirements
             of the protocol.

          -  Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

        Naive Group

          -  Male and female individuals of similar age (approximately 12-20 years) to follow-on
             subjects from V102_15 (NCT02212457) trial.

          -  Who have not received any meningococcal vaccination since birth

          -  Individuals who have given their written informed consent or assent after the nature
             of the study has been explained according to local regulatory requirements, prior to
             study entry. If the subject is under age 18 at the time of enrollment, the parent(s)/
             legal guardian(s) of the subject should have given their written consent.

          -  Individuals of who the investigator believes can and will comply with the requirements
             of the protocol.

          -  Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

        Exclusion Criteria:

        Follow-on Participants:

          -  Follow-on individuals not eligible to be enrolled in the study are those with:

          -  History of any meningococcal vaccine administration since last meningococcal
             vaccination administered in V102_15 (NCT02212457) parent study.

          -  Current or previous, confirmed or suspected disease caused by N. meningitidis, since
             termination from parent study.

          -  Household contact with and/or intimate exposure to an individual with any laboratory
             confirmed N. meningitidis infection within 60 days of enrollment.

          -  If the subject is female of childbearing potential, sexually active, and has not used
             any of the acceptable contraceptive methods for at least 2 months prior to study entry
             and for the duration of the trial.

          -  Pregnancy or breast-feeding

          -  History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component including diphtheria toxoid (CRM197) and latex.

          -  Progressive, unstable or uncontrolled clinical conditions.

          -  Any confirmed or suspected condition with impaired/altered function of immune system.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             three months prior to the study vaccination or planned use throughout the study
             period. (For corticosteroids, this means prednisone, or equivalent, ≥ 20 mg/day.
             Inhaled, intranasal and topical steroids are allowed).

          -  Administration of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation in the 3 months prior to study enrolment.

          -  Received an investigational or non-registered medicinal product within 30 days prior
             to informed consent.

          -  Administration of any vaccine within 14 days or 28 days prior to enrollment in the
             study, or within 7 days after vaccination in the study.

          -  Clinical conditions representing a contraindication to intramuscular vaccination
             and/or blood draws.

          -  Who have received systemic antibiotic treatment within 3 days prior to any blood draw

          -  Any other clinical condition that, in the opinion of the investigator, might pose
             additional risk to the subject due to participation in the study.

        Naive Individuals

          -  Naive individuals not eligible to be enrolled in the study are those with:

          -  History of any meningococcal vaccine administration since birth.

          -  Current or previous, confirmed or suspected disease caused by N. meningitidis.

          -  Household contact with and/or intimate exposure to an individual with any laboratory
             confirmed N. meningitidis infection within 60 days of enrollment.

          -  If the subject is female of childbearing potential, sexually active, and has not used
             any of the acceptable contraceptive methods for at least 2 months prior to study entry
             and for the duration of the trial.

          -  Pregnancy or breast-feeding.

          -  History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component including diphtheria toxoid (CRM197) and latex.

          -  Progressive, unstable or uncontrolled clinical conditions.

          -  Any confirmed or suspected condition with impaired/altered function of immune system.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within 30
             days prior to the study enrolment. (For corticosteroids, this means prednisone, or
             equivalent, ≥ 20 mg/kg/day. Inhaled, intranasal and topical steroids are allowed).

          -  Administration of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation in the past 3 months or planned use throughout the study
             period.

          -  Received an investigational or non-registered medicinal product within 30 days prior
             to informed consent.

          -  Individuals who are part of study personnel or close family members conducting this
             study.

          -  Administration of any vaccine within 14 days or 28 days prior to enrollment in the
             study, or within 7 days after first vaccination, and/or planned use of any vaccine 7
             days prior to and 7 days after second vaccination.

          -  Clinical conditions representing a contraindication to intramuscular vaccination
             and/or blood draws.

          -  Who have received systemic antibiotic treatment within 3 days prior to any blood draw

          -  Any other clinical condition that, in the opinion of the investigator, might pose
             additional risk to the subject due to participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80 542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91 347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <results_first_submitted>February 12, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningococcal disease</keyword>
  <keyword>meningitis</keyword>
  <keyword>booster</keyword>
  <keyword>antibody persistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02946385/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02946385/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects enrolled in the study started the study.</recruitment_details>
      <pre_assignment_details>Participant flow,baseline characteristics &amp; immunogenicity analyses were performed on &quot;randomized&quot; population &amp; Safety analysis on &quot;treated&quot; population.2 subjects from Naïve_ABCWY group received rMenB+OMV vaccine &amp; not MenABCWY.Hence,number of subjects analyzed in Naïve_B &amp; Naive_ABCWY groups in treated population differ from randomized population</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B_0_2</title>
          <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
        </group>
        <group group_id="P2">
          <title>ABCWY_0_2</title>
          <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="P3">
          <title>Naive_B</title>
          <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
        </group>
        <group group_id="P4">
          <title>ABCWY_0_6</title>
          <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="P5">
          <title>Naive_ABCWY</title>
          <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
        </group>
        <group group_id="P6">
          <title>ABCWY_0_2_6</title>
          <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="101"/>
                <participants group_id="P6" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="99"/>
                <participants group_id="P6" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B_0_2</title>
          <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
        </group>
        <group group_id="B2">
          <title>ABCWY_0_2</title>
          <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="B3">
          <title>Naive_B</title>
          <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
        </group>
        <group group_id="B4">
          <title>ABCWY_0_6</title>
          <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="B5">
          <title>Naive_ABCWY</title>
          <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
        </group>
        <group group_id="B6">
          <title>ABCWY_0_2_6</title>
          <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="B7">
          <title>TOTAL</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="74"/>
            <count group_id="B5" value="101"/>
            <count group_id="B6" value="77"/>
            <count group_id="B7" value="604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.8" spread="3.06"/>
                    <measurement group_id="B2" value="16.6" spread="3.15"/>
                    <measurement group_id="B3" value="16.2" spread="2.8"/>
                    <measurement group_id="B4" value="17.3" spread="2.96"/>
                    <measurement group_id="B5" value="16.5" spread="2.78"/>
                    <measurement group_id="B6" value="17.1" spread="2.98"/>
                    <measurement group_id="B7" value="16.7" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="363"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>AMERICAN INDIAN OR ALASKA NATIVE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASIAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTHER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHITE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="100"/>
                    <measurement group_id="B6" value="75"/>
                    <measurement group_id="B7" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last Meningococcal Vaccination in Follow-on Subjects in V102_15 and at Day 1 in Naive Subjects</title>
        <description>The immunogenicity of MenABCWY or rMenB+OMV vaccines, is measured as the percentage of subjects with High-Throughput Human Serum Bactericidal Assay (HT-hSBA) titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>At 24 months after the last meningococcal vaccination for all follow-on subjects and at Day 1 in the extension study for naive subjects</time_frame>
        <population>Subjects in full analysis set(FAS) persistence(24 months after last vaccination in V102_15/Day 1)who were randomized(if naive) &amp; provided evaluable serum sample with hSBA results for atleast 1 serogroup B test strain/serogroups A,C,W/Y at Day 1 in extension study.Subjects in group B_0_2 did not receive MenACWY vaccination in the parent study</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ALL</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY or rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last Meningococcal Vaccination in Follow-on Subjects in V102_15 and at Day 1 in Naive Subjects</title>
          <description>The immunogenicity of MenABCWY or rMenB+OMV vaccines, is measured as the percentage of subjects with High-Throughput Human Serum Bactericidal Assay (HT-hSBA) titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>Subjects in full analysis set(FAS) persistence(24 months after last vaccination in V102_15/Day 1)who were randomized(if naive) &amp; provided evaluable serum sample with hSBA results for atleast 1 serogroup B test strain/serogroups A,C,W/Y at Day 1 in extension study.Subjects in group B_0_2 did not receive MenACWY vaccination in the parent study</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="125"/>
                <count group_id="O5" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="123"/>
                    <count group_id="O5" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11.8" upper_limit="26.2"/>
                    <measurement group_id="O2" value="16" lower_limit="8.7" upper_limit="26.6"/>
                    <measurement group_id="O3" value="25" lower_limit="15.5" upper_limit="36.6"/>
                    <measurement group_id="O4" value="17" lower_limit="10.9" upper_limit="24.9"/>
                    <measurement group_id="O5" value="5" lower_limit="2.1" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="124"/>
                    <count group_id="O5" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="62.1" upper_limit="78.6"/>
                    <measurement group_id="O2" value="81" lower_limit="70.3" upper_limit="89.3"/>
                    <measurement group_id="O3" value="73" lower_limit="61.4" upper_limit="82.6"/>
                    <measurement group_id="O4" value="81" lower_limit="73.5" upper_limit="87.9"/>
                    <measurement group_id="O5" value="34" lower_limit="27.3" upper_limit="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="124"/>
                    <count group_id="O5" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9.9" upper_limit="23.3"/>
                    <measurement group_id="O2" value="15" lower_limit="7.6" upper_limit="24.7"/>
                    <measurement group_id="O3" value="18" lower_limit="9.7" upper_limit="28.2"/>
                    <measurement group_id="O4" value="15" lower_limit="9.5" upper_limit="22.9"/>
                    <measurement group_id="O5" value="3" lower_limit="0.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="125"/>
                    <count group_id="O5" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="21.6" upper_limit="38.1"/>
                    <measurement group_id="O2" value="31" lower_limit="20.5" upper_limit="42.4"/>
                    <measurement group_id="O3" value="36" lower_limit="24.7" upper_limit="47.7"/>
                    <measurement group_id="O4" value="28" lower_limit="20.3" upper_limit="36.7"/>
                    <measurement group_id="O5" value="17" lower_limit="12.3" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="9.4" upper_limit="22.7"/>
                    <measurement group_id="O2" value="25" lower_limit="15.5" upper_limit="36.6"/>
                    <measurement group_id="O3" value="27" lower_limit="17.4" upper_limit="38.6"/>
                    <measurement group_id="O5" value="3" lower_limit="0.6" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="75.8" upper_limit="89.5"/>
                    <measurement group_id="O2" value="86" lower_limit="76.5" upper_limit="93.3"/>
                    <measurement group_id="O3" value="85" lower_limit="75.0" upper_limit="92.3"/>
                    <measurement group_id="O5" value="32" lower_limit="23.0" upper_limit="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42.9" upper_limit="60.9"/>
                    <measurement group_id="O2" value="73" lower_limit="61.9" upper_limit="82.9"/>
                    <measurement group_id="O3" value="64" lower_limit="51.7" upper_limit="74.9"/>
                    <measurement group_id="O5" value="27" lower_limit="18.1" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="43.3" upper_limit="61.3"/>
                    <measurement group_id="O2" value="75" lower_limit="63.9" upper_limit="84.7"/>
                    <measurement group_id="O3" value="62" lower_limit="49.5" upper_limit="72.8"/>
                    <measurement group_id="O5" value="7" lower_limit="2.9" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last Meningococcal Vaccination in Follow-on Subjects in V102_15 and at Day 1 in Naive Subjects</title>
        <description>The immunogenicity of MenABCWY or rMenB+OMV vaccines, is measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>At 24 months after the last meningococcal vaccination for all follow-on subjects and at Day 1 in the extension study for naive subjects</time_frame>
        <population>Subjects in full analysis set(FAS) persistence(24 months after last vaccination in V102_15/Day 1)who were randomized(if naive) &amp; provided evaluable serum sample with hSBA results for atleast 1 serogroup B test strain/serogroups A,C,W/Y at Day 1 in extension study.Subjects in group B_0_2 did not receive MenACWY vaccination in the parent study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ALL</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY or rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last Meningococcal Vaccination in Follow-on Subjects in V102_15 and at Day 1 in Naive Subjects</title>
          <description>The immunogenicity of MenABCWY or rMenB+OMV vaccines, is measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>Subjects in full analysis set(FAS) persistence(24 months after last vaccination in V102_15/Day 1)who were randomized(if naive) &amp; provided evaluable serum sample with hSBA results for atleast 1 serogroup B test strain/serogroups A,C,W/Y at Day 1 in extension study.Subjects in group B_0_2 did not receive MenACWY vaccination in the parent study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="125"/>
                <count group_id="O5" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="123"/>
                    <count group_id="O5" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="1.68" upper_limit="2.50"/>
                    <measurement group_id="O2" value="2" lower_limit="1.55" upper_limit="2.57"/>
                    <measurement group_id="O3" value="2.55" lower_limit="1.98" upper_limit="3.30"/>
                    <measurement group_id="O4" value="2.02" lower_limit="1.66" upper_limit="2.45"/>
                    <measurement group_id="O5" value="1.21" lower_limit="1.04" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="124"/>
                    <count group_id="O5" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="O2" value="19" lower_limit="14" upper_limit="27"/>
                    <measurement group_id="O3" value="15" lower_limit="11" upper_limit="22"/>
                    <measurement group_id="O4" value="20" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O5" value="3.63" lower_limit="2.94" upper_limit="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="124"/>
                    <count group_id="O5" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="1.48" upper_limit="2.16"/>
                    <measurement group_id="O2" value="1.72" lower_limit="1.34" upper_limit="2.19"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.64" upper_limit="2.69"/>
                    <measurement group_id="O4" value="1.72" lower_limit="1.42" upper_limit="2.08"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.95" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="125"/>
                    <count group_id="O5" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="3.09" upper_limit="5.05"/>
                    <measurement group_id="O2" value="4.22" lower_limit="3.07" upper_limit="5.80"/>
                    <measurement group_id="O3" value="5.2" lower_limit="3.77" upper_limit="7.18"/>
                    <measurement group_id="O4" value="4.21" lower_limit="3.29" upper_limit="5.38"/>
                    <measurement group_id="O5" value="2.27" lower_limit="1.87" upper_limit="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.72" upper_limit="2.95"/>
                    <measurement group_id="O2" value="4.52" lower_limit="3.18" upper_limit="6.44"/>
                    <measurement group_id="O3" value="4.89" lower_limit="3.45" upper_limit="6.94"/>
                    <measurement group_id="O5" value="1.21" lower_limit="0.89" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="14" upper_limit="23"/>
                    <measurement group_id="O2" value="29" lower_limit="21" upper_limit="41"/>
                    <measurement group_id="O3" value="20" lower_limit="14" upper_limit="28"/>
                    <measurement group_id="O5" value="2.92" lower_limit="2.19" upper_limit="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="29" upper_limit="51"/>
                    <measurement group_id="O2" value="53" lower_limit="36" upper_limit="76"/>
                    <measurement group_id="O3" value="44" lower_limit="30" upper_limit="64"/>
                    <measurement group_id="O5" value="6.32" lower_limit="4.59" upper_limit="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.19" lower_limit="6.85" upper_limit="12"/>
                    <measurement group_id="O2" value="29" lower_limit="20" upper_limit="43"/>
                    <measurement group_id="O3" value="16" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O5" value="1.52" lower_limit="1.09" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers ≥ LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</title>
        <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with HT-hSBA titers greater than or equal to (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>Day 31: One month after a booster dose of MenABCWY given at 24 months after last MenABCWY vaccination in groups: ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 and after first dose of MenABCWY in Naive_ABCWY Group</time_frame>
        <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers ≥ LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</title>
          <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with HT-hSBA titers greater than or equal to (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79.3" upper_limit="91.9"/>
                    <measurement group_id="O2" value="85" lower_limit="75.3" upper_limit="92.4"/>
                    <measurement group_id="O3" value="95" lower_limit="86.6" upper_limit="98.5"/>
                    <measurement group_id="O4" value="29" lower_limit="20.4" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="62" lower_limit="51.7" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="60.5" upper_limit="77.2"/>
                    <measurement group_id="O2" value="68" lower_limit="56.7" upper_limit="78.6"/>
                    <measurement group_id="O3" value="81" lower_limit="69.5" upper_limit="88.9"/>
                    <measurement group_id="O4" value="27" lower_limit="18.6" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79.3" upper_limit="91.9"/>
                    <measurement group_id="O2" value="84" lower_limit="74.4" upper_limit="91.7"/>
                    <measurement group_id="O3" value="81" lower_limit="69.9" upper_limit="89.1"/>
                    <measurement group_id="O4" value="30" lower_limit="21.2" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.3" upper_limit="99.81"/>
                    <measurement group_id="O2" value="100" lower_limit="95.3" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="92.6" upper_limit="99.97"/>
                    <measurement group_id="O4" value="55" lower_limit="44.7" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="91" lower_limit="83.6" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="78" lower_limit="68.6" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95.3" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="92.6" upper_limit="99.97"/>
                    <measurement group_id="O4" value="71" lower_limit="61.4" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</title>
        <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
        <time_frame>Day 31: One month after a booster dose of MenABCWY given at 24 months after last MenABCWY vaccination in groups: ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 and after first dose of MenABCWY in Naive_ABCWY Group</time_frame>
        <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</title>
          <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
          <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="44.8" upper_limit="63.3"/>
                    <measurement group_id="O2" value="49" lower_limit="37.4" upper_limit="61.3"/>
                    <measurement group_id="O3" value="65" lower_limit="53.1" upper_limit="76.1"/>
                    <measurement group_id="O4" value="8" lower_limit="3.6" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="84.1" upper_limit="95.0"/>
                    <measurement group_id="O2" value="95" lower_limit="86.7" upper_limit="98.5"/>
                    <measurement group_id="O3" value="97" lower_limit="90.5" upper_limit="99.67"/>
                    <measurement group_id="O4" value="17" lower_limit="10.3" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15.2" upper_limit="30.3"/>
                    <measurement group_id="O2" value="17" lower_limit="9.6" upper_limit="27.8"/>
                    <measurement group_id="O3" value="14" lower_limit="6.9" upper_limit="24.1"/>
                    <measurement group_id="O4" value="16" lower_limit="9.5" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="29.1" upper_limit="46.7"/>
                    <measurement group_id="O2" value="19" lower_limit="10.6" upper_limit="29.3"/>
                    <measurement group_id="O3" value="17" lower_limit="8.9" upper_limit="27.3"/>
                    <measurement group_id="O4" value="11" lower_limit="5.7" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="74.2" upper_limit="88.4"/>
                    <measurement group_id="O2" value="83" lower_limit="72.7" upper_limit="91.1"/>
                    <measurement group_id="O3" value="88" lower_limit="77.9" upper_limit="94.2"/>
                    <measurement group_id="O4" value="23" lower_limit="14.8" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="86" lower_limit="76.5" upper_limit="93.3"/>
                    <measurement group_id="O3" value="93" lower_limit="84.7" upper_limit="97.7"/>
                    <measurement group_id="O4" value="54" lower_limit="43.2" upper_limit="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="86.7" upper_limit="96.6"/>
                    <measurement group_id="O2" value="92" lower_limit="82.7" upper_limit="96.9"/>
                    <measurement group_id="O3" value="85" lower_limit="74.0" upper_limit="92.0"/>
                    <measurement group_id="O4" value="36" lower_limit="26.6" upper_limit="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87.9" upper_limit="97.2"/>
                    <measurement group_id="O2" value="89" lower_limit="79.5" upper_limit="95.1"/>
                    <measurement group_id="O3" value="90" lower_limit="81.0" upper_limit="96.0"/>
                    <measurement group_id="O4" value="46" lower_limit="35.6" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</title>
        <description>The immunogenicity of MenABCWY vaccine, was measured as the HT-hSBA Geometric Mean Titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y . The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>Day 31: One month after a booster dose of MenABCWY given at 24 months after last MenABCWY vaccination in groups: ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 and after first dose of MenABCWY in Naive_ABCWY Group</time_frame>
        <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at Day 31 After MenABCWY Vaccination in V102_15E1</title>
          <description>The immunogenicity of MenABCWY vaccine, was measured as the HT-hSBA Geometric Mean Titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y . The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="25" upper_limit="41"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O3" value="61" lower_limit="44" upper_limit="85"/>
                    <measurement group_id="O4" value="3.12" lower_limit="2.34" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="580" lower_limit="467" upper_limit="722"/>
                    <measurement group_id="O2" value="529" lower_limit="400" upper_limit="700"/>
                    <measurement group_id="O3" value="544" lower_limit="408" upper_limit="725"/>
                    <measurement group_id="O4" value="11" lower_limit="8.25" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O2" value="13" lower_limit="9.04" upper_limit="18"/>
                    <measurement group_id="O3" value="16" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O4" value="3.14" lower_limit="2.32" upper_limit="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="26" upper_limit="41"/>
                    <measurement group_id="O2" value="25" lower_limit="18" upper_limit="33"/>
                    <measurement group_id="O3" value="21" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="O4" value="4.48" lower_limit="3.47" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271" lower_limit="211" upper_limit="348"/>
                    <measurement group_id="O2" value="267" lower_limit="194" upper_limit="367"/>
                    <measurement group_id="O3" value="340" lower_limit="245" upper_limit="472"/>
                    <measurement group_id="O4" value="17" lower_limit="13" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628" lower_limit="498" upper_limit="791"/>
                    <measurement group_id="O2" value="602" lower_limit="446" upper_limit="812"/>
                    <measurement group_id="O3" value="529" lower_limit="391" upper_limit="718"/>
                    <measurement group_id="O4" value="48" lower_limit="37" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1309" lower_limit="1062" upper_limit="1614"/>
                    <measurement group_id="O2" value="1078" lower_limit="823" upper_limit="1413"/>
                    <measurement group_id="O3" value="979" lower_limit="746" upper_limit="1286"/>
                    <measurement group_id="O4" value="129" lower_limit="102" upper_limit="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616" lower_limit="479" upper_limit="791"/>
                    <measurement group_id="O2" value="606" lower_limit="439" upper_limit="836"/>
                    <measurement group_id="O3" value="578" lower_limit="415" upper_limit="803"/>
                    <measurement group_id="O4" value="33" lower_limit="25" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and N. Meningitidis Serogroups A, C, W and Y at 24 Months At Days 1, 6, 31 in V102_15 Follow-on Subjects and at Day 1, 66, 91 in Naive Subjects, in MenABCWY Groups</title>
        <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>At Day 1, Day 6 and 31(after booster dose of MenABCWY given at 24 months after last MenABCWY vaccination) in ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 groups and at Day 1, Day 66 and 91(i.e. day 6 and 1 month after dose 2 of MenABCWY) in Naive_ABCWY Group</time_frame>
        <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster [follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and N. Meningitidis Serogroups A, C, W and Y at 24 Months At Days 1, 6, 31 in V102_15 Follow-on Subjects and at Day 1, 66, 91 in Naive Subjects, in MenABCWY Groups</title>
          <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster [follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12.0" upper_limit="26.6"/>
                    <measurement group_id="O2" value="17" lower_limit="8.9" upper_limit="27.3"/>
                    <measurement group_id="O3" value="26" lower_limit="16.0" upper_limit="37.6"/>
                    <measurement group_id="O4" value="6" lower_limit="2.4" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="54.6" upper_limit="72.5"/>
                    <measurement group_id="O2" value="82" lower_limit="71.1" upper_limit="90.0"/>
                    <measurement group_id="O3" value="89" lower_limit="78.7" upper_limit="94.9"/>
                    <measurement group_id="O4" value="64" lower_limit="53.3" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="78.1" upper_limit="91.5"/>
                    <measurement group_id="O2" value="85" lower_limit="74.3" upper_limit="92.1"/>
                    <measurement group_id="O3" value="94" lower_limit="86.0" upper_limit="98.4"/>
                    <measurement group_id="O4" value="72" lower_limit="62.2" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="62.4" upper_limit="78.9"/>
                    <measurement group_id="O2" value="81" lower_limit="70.3" upper_limit="89.3"/>
                    <measurement group_id="O3" value="74" lower_limit="61.9" upper_limit="83.3"/>
                    <measurement group_id="O4" value="32" lower_limit="23.1" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.3" upper_limit="99.81"/>
                    <measurement group_id="O2" value="100" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97" lower_limit="90.3" upper_limit="99.66"/>
                    <measurement group_id="O4" value="91" lower_limit="82.9" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="95.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="98" lower_limit="92.7" upper_limit="99.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9.9" upper_limit="23.3"/>
                    <measurement group_id="O2" value="14" lower_limit="6.7" upper_limit="23.5"/>
                    <measurement group_id="O3" value="18" lower_limit="10.1" upper_limit="29.3"/>
                    <measurement group_id="O4" value="2" lower_limit="0.26" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="35.3" upper_limit="53.2"/>
                    <measurement group_id="O2" value="53" lower_limit="40.7" upper_limit="64.4"/>
                    <measurement group_id="O3" value="66" lower_limit="54.0" upper_limit="77.0"/>
                    <measurement group_id="O4" value="56" lower_limit="45.8" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="60.5" upper_limit="77.2"/>
                    <measurement group_id="O2" value="70" lower_limit="58.5" upper_limit="80.3"/>
                    <measurement group_id="O3" value="80" lower_limit="69.1" upper_limit="88.8"/>
                    <measurement group_id="O4" value="73" lower_limit="63.3" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="22.0" upper_limit="38.7"/>
                    <measurement group_id="O2" value="31" lower_limit="20.5" upper_limit="42.4"/>
                    <measurement group_id="O3" value="37" lower_limit="25.5" upper_limit="48.9"/>
                    <measurement group_id="O4" value="18" lower_limit="10.8" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="55.4" upper_limit="72.9"/>
                    <measurement group_id="O2" value="72" lower_limit="60.4" upper_limit="81.8"/>
                    <measurement group_id="O3" value="76" lower_limit="64.5" upper_limit="85.4"/>
                    <measurement group_id="O4" value="55" lower_limit="44.2" upper_limit="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79.0" upper_limit="91.8"/>
                    <measurement group_id="O2" value="85" lower_limit="75.3" upper_limit="92.4"/>
                    <measurement group_id="O3" value="80" lower_limit="69.1" upper_limit="88.8"/>
                    <measurement group_id="O4" value="62" lower_limit="51.6" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9.6" upper_limit="23.2"/>
                    <measurement group_id="O2" value="25" lower_limit="15.8" upper_limit="37.1"/>
                    <measurement group_id="O3" value="28" lower_limit="17.9" upper_limit="39.6"/>
                    <measurement group_id="O4" value="3" lower_limit="0.7" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="80.5" upper_limit="93.0"/>
                    <measurement group_id="O2" value="96" lower_limit="88.1" upper_limit="99.1"/>
                    <measurement group_id="O3" value="89" lower_limit="79.3" upper_limit="95.1"/>
                    <measurement group_id="O4" value="82" lower_limit="72.4" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94.2" upper_limit="99.80"/>
                    <measurement group_id="O2" value="100" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="92.5" upper_limit="99.96"/>
                    <measurement group_id="O4" value="94" lower_limit="86.5" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="75.8" upper_limit="89.5"/>
                    <measurement group_id="O2" value="86" lower_limit="76.5" upper_limit="93.3"/>
                    <measurement group_id="O3" value="86" lower_limit="75.9" upper_limit="93.1"/>
                    <measurement group_id="O4" value="32" lower_limit="22.4" upper_limit="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.7" upper_limit="99.98"/>
                    <measurement group_id="O2" value="100" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="92.5" upper_limit="99.96"/>
                    <measurement group_id="O4" value="99" lower_limit="94.3" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="95.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="96.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42.8" upper_limit="61.2"/>
                    <measurement group_id="O2" value="73" lower_limit="61.4" upper_limit="83.1"/>
                    <measurement group_id="O3" value="64" lower_limit="51.3" upper_limit="75.0"/>
                    <measurement group_id="O4" value="27" lower_limit="18.2" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95.5" upper_limit="99.98"/>
                    <measurement group_id="O2" value="99" lower_limit="92.4" upper_limit="99.96"/>
                    <measurement group_id="O3" value="97" lower_limit="89.9" upper_limit="99.65"/>
                    <measurement group_id="O4" value="98" lower_limit="92.4" upper_limit="99.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="94.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="98" lower_limit="92.4" upper_limit="99.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42.9" upper_limit="61.0"/>
                    <measurement group_id="O2" value="76" lower_limit="64.9" upper_limit="85.6"/>
                    <measurement group_id="O3" value="62" lower_limit="49.7" upper_limit="73.2"/>
                    <measurement group_id="O4" value="7" lower_limit="3.0" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92.0" upper_limit="99.1"/>
                    <measurement group_id="O2" value="100" lower_limit="95.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97" lower_limit="90.2" upper_limit="99.66"/>
                    <measurement group_id="O4" value="95" lower_limit="88.0" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="92.4" upper_limit="99.96"/>
                    <measurement group_id="O4" value="95" lower_limit="88.0" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y At Days 6, 31 in Follow-on Subjects in V102_15 and at Day 66, 91 in Naive Subjects, in MenABCWY Groups</title>
        <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
        <time_frame>At Day 6 and 31(after booster dose of MenABCWY given at 24 months after last MenABCWY vaccination) in ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 groups and at Day 66 and 91(i.e. day 6 and 1 month after dose 2 of MenABCWY) in Naive_ABCWY Group</time_frame>
        <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y At Days 6, 31 in Follow-on Subjects in V102_15 and at Day 66, 91 in Naive Subjects, in MenABCWY Groups</title>
          <description>The immunogenicity of MenABCWY vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains and serogroups A,C, W and Y. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
          <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab, Day 6 Post vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="18.4" upper_limit="34.9"/>
                    <measurement group_id="O2" value="36" lower_limit="25.1" upper_limit="48.3"/>
                    <measurement group_id="O3" value="50" lower_limit="37.8" upper_limit="62.2"/>
                    <measurement group_id="O4" value="30" lower_limit="20.8" upper_limit="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, One month Post vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="45.2" upper_limit="63.8"/>
                    <measurement group_id="O2" value="49" lower_limit="36.7" upper_limit="60.7"/>
                    <measurement group_id="O3" value="64" lower_limit="51.9" upper_limit="75.4"/>
                    <measurement group_id="O4" value="24" lower_limit="16.2" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79.1" upper_limit="91.9"/>
                    <measurement group_id="O2" value="92" lower_limit="83.2" upper_limit="97.0"/>
                    <measurement group_id="O3" value="85" lower_limit="74.3" upper_limit="92.1"/>
                    <measurement group_id="O4" value="65" lower_limit="54.2" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="83.8" upper_limit="94.9"/>
                    <measurement group_id="O2" value="95" lower_limit="86.7" upper_limit="98.5"/>
                    <measurement group_id="O3" value="97" lower_limit="90.3" upper_limit="99.66"/>
                    <measurement group_id="O4" value="73" lower_limit="62.9" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1.3" upper_limit="8.9"/>
                    <measurement group_id="O2" value="8" lower_limit="3.0" upper_limit="16.8"/>
                    <measurement group_id="O3" value="14" lower_limit="7.0" upper_limit="24.4"/>
                    <measurement group_id="O4" value="24" lower_limit="16.2" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="15.2" upper_limit="30.3"/>
                    <measurement group_id="O2" value="18" lower_limit="9.7" upper_limit="28.2"/>
                    <measurement group_id="O3" value="14" lower_limit="7.0" upper_limit="24.4"/>
                    <measurement group_id="O4" value="21" lower_limit="13.5" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8.2" upper_limit="21.0"/>
                    <measurement group_id="O2" value="11" lower_limit="4.7" upper_limit="19.9"/>
                    <measurement group_id="O3" value="8" lower_limit="3.2" upper_limit="17.5"/>
                    <measurement group_id="O4" value="8" lower_limit="3.7" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="28.6" upper_limit="46.2"/>
                    <measurement group_id="O2" value="19" lower_limit="10.6" upper_limit="29.3"/>
                    <measurement group_id="O3" value="15" lower_limit="8.0" upper_limit="26.0"/>
                    <measurement group_id="O4" value="16" lower_limit="9.1" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="56.4" upper_limit="73.9"/>
                    <measurement group_id="O2" value="76" lower_limit="64.5" upper_limit="85.4"/>
                    <measurement group_id="O3" value="75" lower_limit="63.4" upper_limit="84.5"/>
                    <measurement group_id="O4" value="53" lower_limit="42.1" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="74.0" upper_limit="88.3"/>
                    <measurement group_id="O2" value="85" lower_limit="74.0" upper_limit="92.0"/>
                    <measurement group_id="O3" value="88" lower_limit="77.6" upper_limit="94.1"/>
                    <measurement group_id="O4" value="46" lower_limit="35.8" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="81.3" upper_limit="93.2"/>
                    <measurement group_id="O2" value="86" lower_limit="76.5" upper_limit="93.3"/>
                    <measurement group_id="O3" value="78" lower_limit="66.4" upper_limit="86.7"/>
                    <measurement group_id="O4" value="83" lower_limit="74.1" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88.0" upper_limit="97.2"/>
                    <measurement group_id="O2" value="86" lower_limit="76.5" upper_limit="93.3"/>
                    <measurement group_id="O3" value="93" lower_limit="84.5" upper_limit="97.7"/>
                    <measurement group_id="O4" value="91" lower_limit="82.8" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="71.9" upper_limit="86.9"/>
                    <measurement group_id="O2" value="85" lower_limit="74.0" upper_limit="92.0"/>
                    <measurement group_id="O3" value="75" lower_limit="63.5" upper_limit="84.9"/>
                    <measurement group_id="O4" value="62" lower_limit="51.7" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="86.3" upper_limit="96.5"/>
                    <measurement group_id="O2" value="92" lower_limit="82.5" upper_limit="96.8"/>
                    <measurement group_id="O3" value="84" lower_limit="73.3" upper_limit="91.8"/>
                    <measurement group_id="O4" value="71" lower_limit="60.6" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="72.8" upper_limit="87.3"/>
                    <measurement group_id="O2" value="85" lower_limit="74.3" upper_limit="92.1"/>
                    <measurement group_id="O3" value="79" lower_limit="67.6" upper_limit="87.7"/>
                    <measurement group_id="O4" value="78" lower_limit="67.9" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87.8" upper_limit="97.2"/>
                    <measurement group_id="O2" value="89" lower_limit="79.3" upper_limit="95.1"/>
                    <measurement group_id="O3" value="90" lower_limit="80.7" upper_limit="95.9"/>
                    <measurement group_id="O4" value="83" lower_limit="73.8" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in MenABCWY Groups</title>
        <description>The immunogenicity of MenABCWY vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y . The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>At Day 1, Day 6 and 31(after booster dose of MenABCWY given at 24 months after last MenABCWY vaccination) in ABCWY_0_2, ABCWY_0_6 and ABCWY_0_2_6 groups and at Day 1, Day 66 and 91(i.e. day 6 and 1 month after dose 2 of MenABCWY) in Naive_ABCWY Group</time_frame>
        <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in MenABCWY Groups</title>
          <description>The immunogenicity of MenABCWY vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains and serogroups A,C, W and Y . The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="1.70" upper_limit="2.54"/>
                    <measurement group_id="O2" value="2.04" lower_limit="1.58" upper_limit="2.64"/>
                    <measurement group_id="O3" value="2.62" lower_limit="2.02" upper_limit="3.41"/>
                    <measurement group_id="O4" value="1.28" lower_limit="1.02" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9.77" upper_limit="18"/>
                    <measurement group_id="O2" value="21" lower_limit="14" upper_limit="31"/>
                    <measurement group_id="O3" value="40" lower_limit="27" upper_limit="58"/>
                    <measurement group_id="O4" value="10" lower_limit="7.48" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="24" upper_limit="39"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O3" value="61" lower_limit="44" upper_limit="84"/>
                    <measurement group_id="O4" value="14" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="O2" value="19" lower_limit="14" upper_limit="27"/>
                    <measurement group_id="O3" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O4" value="3.12" lower_limit="2.31" upper_limit="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376" lower_limit="287" upper_limit="493"/>
                    <measurement group_id="O2" value="486" lower_limit="343" upper_limit="690"/>
                    <measurement group_id="O3" value="401" lower_limit="281" upper_limit="571"/>
                    <measurement group_id="O4" value="70" lower_limit="51" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587" lower_limit="496" upper_limit="695"/>
                    <measurement group_id="O2" value="524" lower_limit="421" upper_limit="652"/>
                    <measurement group_id="O3" value="550" lower_limit="440" upper_limit="687"/>
                    <measurement group_id="O4" value="94" lower_limit="77" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="1.47" upper_limit="2.16"/>
                    <measurement group_id="O2" value="1.66" lower_limit="1.30" upper_limit="2.14"/>
                    <measurement group_id="O3" value="2.17" lower_limit="1.68" upper_limit="2.80"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.85" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" lower_limit="4.58" upper_limit="7.92"/>
                    <measurement group_id="O2" value="7.63" lower_limit="5.33" upper_limit="11"/>
                    <measurement group_id="O3" value="12" lower_limit="8.56" upper_limit="18"/>
                    <measurement group_id="O4" value="8.95" lower_limit="6.52" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="O2" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O3" value="17" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O4" value="14" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="3.10" upper_limit="5.09"/>
                    <measurement group_id="O2" value="4.22" lower_limit="3.07" upper_limit="5.80"/>
                    <measurement group_id="O3" value="5.3" lower_limit="3.81" upper_limit="7.35"/>
                    <measurement group_id="O4" value="2.18" lower_limit="1.64" upper_limit="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="17" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O3" value="16" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O4" value="8.68" lower_limit="6.52" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, One month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="26" upper_limit="40"/>
                    <measurement group_id="O2" value="26" lower_limit="20" upper_limit="34"/>
                    <measurement group_id="O3" value="22" lower_limit="16" upper_limit="28"/>
                    <measurement group_id="O4" value="11" lower_limit="8.60" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.75" upper_limit="3.04"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.16" upper_limit="6.48"/>
                    <measurement group_id="O3" value="5.13" lower_limit="3.59" upper_limit="7.34"/>
                    <measurement group_id="O4" value="1.22" lower_limit="0.89" upper_limit="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" lower_limit="98" upper_limit="191"/>
                    <measurement group_id="O2" value="221" lower_limit="143" upper_limit="341"/>
                    <measurement group_id="O3" value="229" lower_limit="149" upper_limit="352"/>
                    <measurement group_id="O4" value="59" lower_limit="41" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis A human Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="222" upper_limit="327"/>
                    <measurement group_id="O2" value="275" lower_limit="213" upper_limit="354"/>
                    <measurement group_id="O3" value="340" lower_limit="264" upper_limit="437"/>
                    <measurement group_id="O4" value="85" lower_limit="68" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="14" upper_limit="23"/>
                    <measurement group_id="O2" value="29" lower_limit="21" upper_limit="41"/>
                    <measurement group_id="O3" value="21" lower_limit="15" upper_limit="29"/>
                    <measurement group_id="O4" value="2.91" lower_limit="2.17" upper_limit="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" lower_limit="414" upper_limit="662"/>
                    <measurement group_id="O2" value="694" lower_limit="511" upper_limit="942"/>
                    <measurement group_id="O3" value="520" lower_limit="381" upper_limit="710"/>
                    <measurement group_id="O4" value="153" lower_limit="117" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis C human Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628" lower_limit="523" upper_limit="753"/>
                    <measurement group_id="O2" value="612" lower_limit="482" upper_limit="776"/>
                    <measurement group_id="O3" value="539" lower_limit="423" upper_limit="686"/>
                    <measurement group_id="O4" value="177" lower_limit="143" upper_limit="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="28" upper_limit="51"/>
                    <measurement group_id="O2" value="51" lower_limit="35" upper_limit="75"/>
                    <measurement group_id="O3" value="44" lower_limit="30" upper_limit="65"/>
                    <measurement group_id="O4" value="6.25" lower_limit="4.48" upper_limit="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820" lower_limit="665" upper_limit="1011"/>
                    <measurement group_id="O2" value="993" lower_limit="756" upper_limit="1304"/>
                    <measurement group_id="O3" value="916" lower_limit="694" upper_limit="1208"/>
                    <measurement group_id="O4" value="279" lower_limit="220" upper_limit="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis W human Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1345" lower_limit="1142" upper_limit="1584"/>
                    <measurement group_id="O2" value="1050" lower_limit="849" upper_limit="1299"/>
                    <measurement group_id="O3" value="999" lower_limit="805" upper_limit="1240"/>
                    <measurement group_id="O4" value="298" lower_limit="247" upper_limit="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.11" lower_limit="6.77" upper_limit="12"/>
                    <measurement group_id="O2" value="31" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="O3" value="17" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O4" value="1.54" lower_limit="1.10" upper_limit="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351" lower_limit="274" upper_limit="449"/>
                    <measurement group_id="O2" value="606" lower_limit="439" upper_limit="837"/>
                    <measurement group_id="O3" value="425" lower_limit="307" upper_limit="589"/>
                    <measurement group_id="O4" value="145" lower_limit="109" upper_limit="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis Y human Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623" lower_limit="517" upper_limit="750"/>
                    <measurement group_id="O2" value="646" lower_limit="506" upper_limit="824"/>
                    <measurement group_id="O3" value="586" lower_limit="458" upper_limit="750"/>
                    <measurement group_id="O4" value="129" lower_limit="104" upper_limit="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HT-hSBA Titers ≥ LLOQ Against 4 Serogroup B Test Strains at Day 31 After rMenB+OMV Vaccination in V102_15E1</title>
        <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>Day 31: One month after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMVl vaccination in B_0_2 Group and after first dose of rMenB+OMV in Naive_B Group</time_frame>
        <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain at Day 31 in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O2">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HT-hSBA Titers ≥ LLOQ Against 4 Serogroup B Test Strains at Day 31 After rMenB+OMV Vaccination in V102_15E1</title>
          <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain at Day 31 in the extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88.6" upper_limit="97.7"/>
                    <measurement group_id="O2" value="28" lower_limit="19.4" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="74" lower_limit="64.7" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79.9" upper_limit="92.4"/>
                    <measurement group_id="O2" value="27" lower_limit="18.1" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.8" upper_limit="98.2"/>
                    <measurement group_id="O2" value="33" lower_limit="23.5" upper_limit="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains at Day 31 After rMenB+OMV Vaccination in V102_15E1</title>
        <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
        <time_frame>Day 31: One month after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination in B_0_2 Group and after first dose of rMenB+OMV in Naive_B Group</time_frame>
        <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain at Day 31 in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O2">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains at Day 31 After rMenB+OMV Vaccination in V102_15E1</title>
          <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
          <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain at Day 31 in the extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="57.5" upper_limit="75.0"/>
                    <measurement group_id="O2" value="15" lower_limit="8.3" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91.8" upper_limit="99.1"/>
                    <measurement group_id="O2" value="19" lower_limit="11.4" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="31.4" upper_limit="49.4"/>
                    <measurement group_id="O2" value="16" lower_limit="9.7" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="43.6" upper_limit="61.9"/>
                    <measurement group_id="O2" value="8" lower_limit="3.7" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, at Day 31 After rMenB+OMV Vaccination in V102_15E1</title>
        <description>The immunogenicity of rMenB+OMV vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>Day 31: One month after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination in B_0_2 Group and after first dose of rMenB+OMV in Naive_B Group</time_frame>
        <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O2">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of Four Serogroup B Test Strains, at Day 31 After rMenB+OMV Vaccination in V102_15E1</title>
          <description>The immunogenicity of rMenB+OMV vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in the FAS immunogenicity (Day 31, after booster dose[follow-on]/first dose[naive]) who were randomized (if naive), received at least one study vaccination and provided evaluable serum sample with results for at least one serogroup B test strain or serogroups A, C, W or Y at Day 31 in the extension study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="39" upper_limit="65"/>
                    <measurement group_id="O2" value="3.48" lower_limit="2.60" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820" lower_limit="658" upper_limit="1023"/>
                    <measurement group_id="O2" value="18" lower_limit="14" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="O2" value="3.14" lower_limit="2.32" upper_limit="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="47" upper_limit="74"/>
                    <measurement group_id="O2" value="4.82" lower_limit="3.72" upper_limit="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains at 24 Months At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in rMenB+OMV Groups</title>
        <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>At Day 1, at Day 6 and 31(after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination) in B_0_2 Group, and at Day 1, at Day 66 and 91(i.e. day 6 and 1 month after second dose of rMenB+OMV) in Naive_B Group</time_frame>
        <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O2">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains at 24 Months At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in rMenB+OMV Groups</title>
          <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with HT-hSBA titers greater or equal than (≥) Lower limit of quantification (LLOQ) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B 96217 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="73.8" upper_limit="88.2"/>
                    <measurement group_id="O2" value="36" lower_limit="26.5" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="92.9" upper_limit="99.5"/>
                    <measurement group_id="O2" value="88" lower_limit="80.0" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98" lower_limit="92.5" upper_limit="99.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="20.1" upper_limit="36.7"/>
                    <measurement group_id="O2" value="16" lower_limit="9.4" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="60.7" upper_limit="77.7"/>
                    <measurement group_id="O2" value="57" lower_limit="45.8" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.6" upper_limit="98.2"/>
                    <measurement group_id="O2" value="72" lower_limit="61.4" upper_limit="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11.3" upper_limit="25.7"/>
                    <measurement group_id="O2" value="3" lower_limit="0.7" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="60.7" upper_limit="77.8"/>
                    <measurement group_id="O2" value="68" lower_limit="57.7" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="88.3" upper_limit="97.6"/>
                    <measurement group_id="O2" value="78" lower_limit="67.9" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9.7" upper_limit="23.4"/>
                    <measurement group_id="O2" value="3" lower_limit="0.7" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="39.6" upper_limit="58.0"/>
                    <measurement group_id="O2" value="62" lower_limit="51.1" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="79.4" upper_limit="92.2"/>
                    <measurement group_id="O2" value="82" lower_limit="72.6" upper_limit="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains At Days 6, 31 in Follow-on Subjects in V102_15 and at Day 66, 91 in Naive Subjects, in rMenB+OMV Groups</title>
        <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
        <time_frame>At Day 6 and 31(after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination) in B_0_2 Group, and at Day 66 and 91(i.e. day 6 and 1 month after second dose of rMenB+OMV) in Naive_B Group</time_frame>
        <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O2">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With 4-Fold Increase in HT-hSBA Titers Against 4 Serogroup B Test Strains At Days 6, 31 in Follow-on Subjects in V102_15 and at Day 66, 91 in Naive Subjects, in rMenB+OMV Groups</title>
          <description>The immunogenicity of rMenB+OMV vaccine, was measured as the percentages of subjects with 4-Fold Increase in HT-hSBA Titers against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. The 4-fold titer rise is defined as: a) for subjects with pre-vaccination hSBA titers ˂ LLOQ, a post-vaccination hSBA ≥ 4 LLOQ; b) for subjects with a pre-vaccination hSBA titers ≥ LLOQ, an increase of at least 4 times of the pre-vaccination hSBA.</description>
          <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="25.0" upper_limit="43.1"/>
                    <measurement group_id="O2" value="22" lower_limit="13.4" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="56.9" upper_limit="75.0"/>
                    <measurement group_id="O2" value="31" lower_limit="21.1" upper_limit="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="69.9" upper_limit="85.5"/>
                    <measurement group_id="O2" value="69" lower_limit="57.3" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92.6" upper_limit="99.5"/>
                    <measurement group_id="O2" value="81" lower_limit="69.9" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7.5" upper_limit="20.6"/>
                    <measurement group_id="O2" value="21" lower_limit="12.2" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="115"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="31.8" upper_limit="50.4"/>
                    <measurement group_id="O2" value="41" lower_limit="30.0" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 6 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13.7" upper_limit="29.2"/>
                    <measurement group_id="O2" value="14" lower_limit="7.5" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084, One month Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="43.1" upper_limit="61.9"/>
                    <measurement group_id="O2" value="24" lower_limit="14.7" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMTs Against Each of Four Serogroup B Test Strains At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in rMenB+OMV Groups</title>
        <description>The immunogenicity of rMenB+OMV vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
        <time_frame>At Day 1, at Day 6 and 31(after a booster dose of rMenB+OMV given at 24 months after last rMenB+OMV vaccination) in B_0_2 Group, and at Day 1, at Day 66 and 91(i.e. day 6 and 1 month after second dose of rMenB+OMV) in Naive_B Group</time_frame>
        <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O2">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMTs Against Each of Four Serogroup B Test Strains At Days 1, 6, 31 in Follow-on Subjects in V102_15 and at Day 1, 66, 91 in Naive Subjects, in rMenB+OMV Groups</title>
          <description>The immunogenicity of rMenB+OMV vaccine, was measured as the HT-hSBA geometric mean titers (GMTs) against N. meningitidis serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.</description>
          <population>All subjects in FAS immunogenicity(Days 6 and 31, after booster[follow-on]/D66 and 91 after dose 2[naive]) who were randomized(if naive), received at least 1 study vaccination and provided evaluable results for at least 1 serogroup B strain or serogroups A, C, W, Y at D1, and at least at D6 or D31(follow-on)/D 66 or D91(naive) in extension study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningitis B M14459 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.67" upper_limit="2.49"/>
                    <measurement group_id="O2" value="1.18" lower_limit="0.94" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O2" value="12" lower_limit="8.41" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M14459 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="38" upper_limit="63"/>
                    <measurement group_id="O2" value="16" lower_limit="12" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O2" value="4.38" lower_limit="3.23" upper_limit="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" lower_limit="259" upper_limit="448"/>
                    <measurement group_id="O2" value="85" lower_limit="63" upper_limit="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B 96217 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="822" lower_limit="692" upper_limit="975"/>
                    <measurement group_id="O2" value="122" lower_limit="100" upper_limit="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.41" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.15" lower_limit="0.92" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="4.83" upper_limit="8.45"/>
                    <measurement group_id="O2" value="9.38" lower_limit="6.83" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B NZ98/254 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="21" upper_limit="34"/>
                    <measurement group_id="O2" value="22" lower_limit="17" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.30" upper_limit="5.45"/>
                    <measurement group_id="O2" value="2.36" lower_limit="1.77" upper_limit="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, Day 6 post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="O2" value="11" lower_limit="8.54" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis B M07-0241084 Ab, One month post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="47" upper_limit="72"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination</title>
        <description>Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).</description>
        <time_frame>within 30 minutes after vaccination at Day 1 (for all subjects) and also Day 61 (for naive subjects only)</time_frame>
        <population>Analysis was done on subjects in Solicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of the subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination solicited adverse events data</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
          <group group_id="O6">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination</title>
          <description>Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).</description>
          <population>Analysis was done on subjects in Solicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of the subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination solicited adverse events data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="126"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="125"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local: Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local: Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Arthralgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Chills</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Loss Of Appetite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Nausea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="125"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indicator: Prevention Of Pain / Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indicator: Treatment Of Pain / Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="126"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited AEs Within 30 Minutes After Vaccination</title>
        <description>An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a subject and/or parent/legal guardian who has signed the informed consent. Number of subjects reporting any unsolicited AE within 30 minutes after each vaccination. Note: unsolicited AEs within 30 minutes were not collected</description>
        <time_frame>Within 30 minutes after vaccination at Day 1 (for all subjects) and also Day 61 (for naive subjects only)</time_frame>
        <population>Analysis was to be done on subjects in Unsolicited Safety Set but was not performed as AEs within 30 minutes after vaccination were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
          <group group_id="O6">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited AEs Within 30 Minutes After Vaccination</title>
          <description>An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a subject and/or parent/legal guardian who has signed the informed consent. Number of subjects reporting any unsolicited AE within 30 minutes after each vaccination. Note: unsolicited AEs within 30 minutes were not collected</description>
          <population>Analysis was to be done on subjects in Unsolicited Safety Set but was not performed as AEs within 30 minutes after vaccination were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.</title>
        <description>Assessed solicited symptoms were pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).</description>
        <time_frame>At Day 1 (6 hours) to Day 7 after vaccination at Day 1 (for all subjects) and Day 61 to Day 67 (for naive subjects only)</time_frame>
        <population>Analysis was done on subjects in Solicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of the subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination solicited adverse events data</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
          <group group_id="O6">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.</title>
          <description>Assessed solicited symptoms were pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).</description>
          <population>Analysis was done on subjects in Solicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of the subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination solicited adverse events data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="126"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local: Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local: Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local: Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="115"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="59"/>
                    <measurement group_id="O6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Loss Of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic: Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indicator: Prevention Of Pain / Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indicator: Treatment Of Pain / Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs, 30 Days After Any Vaccination</title>
        <description>An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a subject and/or parent/legal guardian who has signed the informed consent. Number of subjects reporting any unsolicited AE within 30 minutes after each vaccination.</description>
        <time_frame>From Day 1 to Day 31 for all subjects and Day 61 to Day 91 for naive subjects</time_frame>
        <population>Analysis was done on subjects in Unsolicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination unsolicited adverse events data</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
          <group group_id="O6">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs, 30 Days After Any Vaccination</title>
          <description>An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a subject and/or parent/legal guardian who has signed the informed consent. Number of subjects reporting any unsolicited AE within 30 minutes after each vaccination.</description>
          <population>Analysis was done on subjects in Unsolicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination unsolicited adverse events data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="126"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal</title>
        <description>Serious adverse events (SAEs), medically attended adverse events and AEs leading to withdrawal are reported. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in one or more of the following: -Death, -Is life-threatening,-Required or prolonged hospitalization, -Persistent or significant disability/incapacity, -Congenital anomaly/or birth defect, -An important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above.</description>
        <time_frame>During the entire study period (up to Day 181 for follow-on subjects and up to Day 241 for naive subjects)</time_frame>
        <population>Analysis was done on subjects in Unsolicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination unsolicited adverse events data</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY_0_2</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O2">
            <title>ABCWY_0_2_6</title>
            <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O3">
            <title>ABCWY_0_6</title>
            <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
          </group>
          <group group_id="O4">
            <title>B_0_2</title>
            <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
          </group>
          <group group_id="O5">
            <title>Naive_ABCWY</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
          </group>
          <group group_id="O6">
            <title>Naive_B</title>
            <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal</title>
          <description>Serious adverse events (SAEs), medically attended adverse events and AEs leading to withdrawal are reported. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in one or more of the following: -Death, -Is life-threatening,-Required or prolonged hospitalization, -Persistent or significant disability/incapacity, -Congenital anomaly/or birth defect, -An important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above.</description>
          <population>Analysis was done on subjects in Unsolicited Safety Set: all screened subjects who provided informed consent, demographic and/or other baseline screening measurements, regardless of subject’s randomization and vaccination status in the trial, received subject ID and study vaccination, and provided post-vaccination unsolicited adverse events data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="126"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any medically attended AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected from Day 1 to Day 7, and Unsolicited AEs from Day 1 to Day 30, after any vaccination. SAEs were collected throughout the entire study period (up to Day 181 for follow-on subjects and up to Day 241 for naive subjects).</time_frame>
      <desc>Safety analysis was performed on the treated population.</desc>
      <group_list>
        <group group_id="E1">
          <title>B_0_2</title>
          <description>Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study</description>
        </group>
        <group group_id="E2">
          <title>ABCWY_0_2</title>
          <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="E3">
          <title>Naive_B</title>
          <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study</description>
        </group>
        <group group_id="E4">
          <title>ABCWY_0_6</title>
          <description>Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
        <group group_id="E5">
          <title>Naive_ABCWY</title>
          <description>Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study</description>
        </group>
        <group group_id="E6">
          <title>ABCWY_0_2_6</title>
          <description>Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="96" subjects_at_risk="99"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="39" subjects_affected="26" subjects_at_risk="126"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E3" events="39" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E5" events="39" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Noninfective sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="50" subjects_affected="27" subjects_at_risk="126"/>
                <counts group_id="E2" events="39" subjects_affected="23" subjects_at_risk="127"/>
                <counts group_id="E3" events="62" subjects_affected="26" subjects_at_risk="101"/>
                <counts group_id="E4" events="20" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E5" events="51" subjects_affected="25" subjects_at_risk="99"/>
                <counts group_id="E6" events="12" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="164" subjects_affected="64" subjects_at_risk="126"/>
                <counts group_id="E2" events="114" subjects_affected="58" subjects_at_risk="127"/>
                <counts group_id="E3" events="206" subjects_affected="55" subjects_at_risk="101"/>
                <counts group_id="E4" events="77" subjects_affected="31" subjects_at_risk="74"/>
                <counts group_id="E5" events="201" subjects_affected="59" subjects_at_risk="99"/>
                <counts group_id="E6" events="67" subjects_affected="33" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="129" subjects_affected="59" subjects_at_risk="126"/>
                <counts group_id="E2" events="100" subjects_affected="50" subjects_at_risk="127"/>
                <counts group_id="E3" events="137" subjects_affected="49" subjects_at_risk="101"/>
                <counts group_id="E4" events="67" subjects_affected="27" subjects_at_risk="74"/>
                <counts group_id="E5" events="148" subjects_affected="45" subjects_at_risk="99"/>
                <counts group_id="E6" events="53" subjects_affected="23" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="117" subjects_affected="40" subjects_at_risk="126"/>
                <counts group_id="E2" events="107" subjects_affected="43" subjects_at_risk="127"/>
                <counts group_id="E3" events="172" subjects_affected="43" subjects_at_risk="101"/>
                <counts group_id="E4" events="51" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E5" events="200" subjects_affected="46" subjects_at_risk="99"/>
                <counts group_id="E6" events="58" subjects_affected="23" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="421" subjects_affected="116" subjects_at_risk="126"/>
                <counts group_id="E2" events="321" subjects_affected="108" subjects_at_risk="127"/>
                <counts group_id="E3" events="683" subjects_affected="93" subjects_at_risk="101"/>
                <counts group_id="E4" events="226" subjects_affected="64" subjects_at_risk="74"/>
                <counts group_id="E5" events="593" subjects_affected="95" subjects_at_risk="99"/>
                <counts group_id="E6" events="227" subjects_affected="67" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nail injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="39" subjects_affected="20" subjects_at_risk="126"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E3" events="38" subjects_affected="16" subjects_at_risk="101"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E5" events="49" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E3" events="33" subjects_affected="17" subjects_at_risk="101"/>
                <counts group_id="E4" events="18" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E5" events="38" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="22" subjects_at_risk="126"/>
                <counts group_id="E2" events="36" subjects_affected="26" subjects_at_risk="127"/>
                <counts group_id="E3" events="40" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E4" events="34" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E5" events="57" subjects_affected="26" subjects_at_risk="99"/>
                <counts group_id="E6" events="17" subjects_affected="13" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Spinal flattening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="132" subjects_affected="62" subjects_at_risk="126"/>
                <counts group_id="E2" events="96" subjects_affected="55" subjects_at_risk="127"/>
                <counts group_id="E3" events="160" subjects_affected="46" subjects_at_risk="101"/>
                <counts group_id="E4" events="64" subjects_affected="28" subjects_at_risk="74"/>
                <counts group_id="E5" events="183" subjects_affected="62" subjects_at_risk="99"/>
                <counts group_id="E6" events="41" subjects_affected="20" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Migraine-triggered seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dyssomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Scrotal varicose veins</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>anand.n.harpalani@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

